Edition:
United Kingdom

Aduro Biotech Inc (ADRO.OQ)

ADRO.OQ on NASDAQ Stock Exchange Global Select Market

3.20USD
13 Nov 2018
Change (% chg)

-- (--)
Prev Close
$3.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
110,496
52-wk High
$10.00
52-wk Low
$3.19

Latest Key Developments (Source: Significant Developments)

Aduro Biotech Q2 Loss Per Share $0.31
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.31.Q2 REVENUE $2.6 MILLION VERSUS $5.9 MILLION.Q2 REVENUE VIEW $4.3 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.  Full Article

Aduro Biotech Announces Management Changes
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH INC - JENNIFER LEW HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER.ADURO BIOTECH ANNOUNCES MANAGEMENT CHANGES.ADURO BIOTECH - GREGORY SCHAFER WILL BE STEPPING DOWN AS CHIEF OPERATING OFFICER IN EARLY MARCH.  Full Article

Aduro Biotech Provides Update On CRS-207 Programs
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Aduro Biotech Inc ::ADURO BIOTECH PROVIDES UPDATE ON CRS-207 PROGRAMS.COMPANY HAS DETERMINED THAT IT WILL NOT CONTINUE ADVANCEMENT OF CRS-207.COMPANY WILL WIND DOWN EACH OF ITS TRIALS IN MESOTHELIOMA, OVARIAN AND GASTRIC CANCER FOR CRS-207.EXPECT CURRENT CASH BALANCE TO BE SUFFICIENT TO FUND PLANNED ACTIVITIES FOR NEXT THREE YEARS THROUGH 2020.  Full Article

Aduro Biotech reports Q3 loss per share $0.33
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Aduro Biotech Inc ::Aduro Biotech reports third quarter 2017 financial results.Q3 loss per share $0.33.Q3 revenue $3.8 million versus $3.8 million.Q3 revenue view $6.1 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S.Aduro Biotech Inc - ‍ anticipated 2017 milestones include to initiate phase 1 multiple myeloma trial with bion-1301, an anti-April antibody​.  Full Article